Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen Licenses Xenomics' IP for Leukemia-linked Gene

NEW YORK (GenomeWeb News) - Xenomics said today it has granted a co-exclusive license to Asuragen to use the NPM1 gene to develop diagnostic products for acute myeloid leukemia patients.
Under the sub-license agreement, Asuragen will have access to use the nucleophosmin gene, or NPM1, toward developing tests to diagnose, stratify, and monitor AML patients.
Xenomics holds exclusive rights to a recent discovery at the University of Perugia that has shown that many AML patients have mutations in that gene.
Such a test could help doctors select patients who are most likely to benefit from intensive chemotherapy, "while sparing others with a low probability of benefit from the toxic treatment," the company said.